Variables | n = 140 | GPA, n = 79 | MPA, n = 61 | p |
---|---|---|---|---|
Normal study | 32 (23) | 18 (23) | 14 (23) | 0.9 |
Parenchymal involvement | ||||
Consolidation | 12 (9) | 5 (6) | 7 (12) | 0.2 |
Ground glass opacity | 22 (16) | 11 (14) | 11 (18) | 0.1 |
Distribution | 0.4 | |||
Diffuse | 5 (4) | 3 (4) | 2 (3) | |
Central | 0 (0) | 0 (0) | 0 (0) | |
Peripheral | 2 (1) | 0 (0) | 2 (3) | |
Subpleural sparing | 15 (11) | 8 (10) | 7 (12) | |
Reticulation, peripheral | 10 (7) | 2 (3) | 8 (13) | 0.02 |
Nondependent atelectasis | 12 (9) | 8 (10) | 4 (7) | 0.5 |
Nodular opacities | 34 (24) | 24 (30) | 10 (16) | 0.05 |
Nodules with cavitation | 15 (11) | 14 (16) | 1 (2) | 0.002 |
Bronchiectasis | 27 (19) | 11 (14) | 16 (26) | 0.06 |
Severity | 0.1 | |||
Mild | 21 (15) | 10 (13) | 11 (18) | |
Moderate | 4 (3) | 1 (1) | 3 (5) | |
Severe | 2 (1) | 0 (0) | 2 (3) | |
Distribution | 0.1 | |||
Cylindrical | 25 (18) | 11 (14) | 14 (23) | |
Cystic | 1 (1) | 0 (0) | 1 (2) | |
Cylindrical and cystic | 1 (1) | 0 (0) | 1 (2) | |
Peribronchial thickening | 9 (6) | 3 (4) | 6 (10) | 0.1 |
Bronchial stenosis, subglottic | 8 (6) | 8 (10) | 0 (0) | 0.01 |
Central airway disease | 9 (7) | 9 (11) | 0 (0) | 0.01 |
Emphysema | 18 (13) | 8 (10) | 10 (16) | 0.2 |
Centrilobular | 17 (12) | 8 (10) | 9 (15) | |
Paraseptal | 1 (1) | 0 (0) | 1 (2) | |
Emphysema GRADE | 0.1 | |||
< 5%–25% | 8 (6) | 5 (6) | 3 (5) | |
26%–50% | 4 (3) | 2 (3) | 2 (3) | |
51%–75% | 4 (3) | 0 (0) | 4 (7) | |
> 75% | 2 (1) | 1 (1) | 1 (2) | |
Disease pattern | ||||
Usual interstitial pneumonitis | 10 (7) | 2 (3) | 8 (13) | 0.02 |
Honeycombing | 10 (7) | 2 (3) | 8 (13) | 0.02 |
Pulmonary hemorrhage | 20 (14) | 10 (13) | 10 (16) | 0.5 |
Scarring | 14 (10) | 9 (11) | 5 (8) | 0.5 |
Peribronchovascular nodularity | 29 (21) | 22 (28) | 7 (12) | 0.01 |
Pulmonary venous congestion | 11 (8) | 4 (5) | 7 (12) | 0.2 |
Additional features | ||||
Endoluminal plugging | 5 (4) | 1 (1) | 4 (7) | 0.1 |
Pleural effusion | 27 (19) | 14 (18) | 13 (21) | 0.5 |
Bilateral | 20 (14) | 12 (15) | 8 (13) | |
Unilateral | 7 (5) | 2 (3) | 5 (8) | |
Pericardial effusion | 6 (4) | 3 (4) | 3 (5) | 1.0 |
Lymph node enlargement, ≥ 10 mm | 20 (14) | 11 (14) | 9 (15) | 0.8 |
ANCA: antineutrophil cytoplasmic antibodies; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; GRADE: Grading of Recommendations Assessment, Development, and Evaluation working group.